tratamiento experimental para la Inmunodeficiencia Primaria, RI-002 BLA, aceptado por la FDA

Post author:Patient Worthy Contributor
Post published:October 16, 2016
Post category:Primary Immunodeficiencies Rare Disease

En julio, PatientWorthy publicó las principales noticias de ADMA Biologics, nuevo fármaco prometedor Inc.; RI-002, un tratamiento con IGIV especialidad para pacientes que están inmunocomprometidos. datos RI-002 demostraron la capacidad…

Get Involved

Ready to get involved with Patient Worthy? Share your authentic story with others. Raise awareness and inspire change!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Get Involved

tratamiento experimental para la Inmunodeficiencia Primaria, RI-002 BLA, aceptado por la FDA

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Get Involved

Let’s Work Together!

Keep Up to Date

Learn More